麦角酸二乙酰胺辅助治疗伴或不伴致命疾病的焦虑:随机双盲安慰剂对照II期研究
本研究为研究者发起的双中心、双盲、安慰剂对照、两周期随机顺序交叉设计II期试验,比较口服麦角酸二乙酰胺(LSD,200 μg)与安慰剂辅助治疗对伴或不伴致命疾病的焦虑患者的疗效与安全性。主要终点为末次治疗16周后的状态-特质焦虑量表全局评分,42例患者纳入分析。LSD治疗显著降低焦虑及共病抑郁症状,且急性主观药物效应与神秘体验与长期焦虑改善相关。
要点
- LSD辅助治疗显著降低焦虑评分,末次治疗后16周差异为-16.2(95%CI -27.8至-4.5,p=.007)。
- 共病抑郁症状亦显著改善:汉密尔顿抑郁量表21项差异-7.0(p=.0004),贝克抑郁量表差异-6.1(p=.02)。
- 8例(19%)报告短暂轻微急性不良反应,1例(2%)发生治疗相关严重不良事件(急性短暂焦虑)。
核心结论
- LSD辅助治疗可产生长达16周的焦虑及共病抑郁症状显著且持久的减轻。
研究设计与样本
- 研究者发起的双中心、双盲、安慰剂对照、两周期随机顺序交叉II期试验,每周期口服LSD 200 μg或安慰剂各一次,共42例患者。
主要发现
- LSD组状态-特质焦虑量表全局评分较基线变化的组间差异为-16.2(标准误5.8,95%CI -27.8至-4.5,d=-1.18,p=.007)。
- 汉密尔顿抑郁量表21项评分差异为-7.0(标准误1.9,95%CI -10.8至-3.2,d=-1.1,p=.0004)。
- 贝克抑郁量表评分差异为-6.1(标准误2.6,95%CI -11.4至-0.9,d=-0.72,p=.02)。
- 阳性急性主观药物效应与神秘型体验与焦虑症状的长期减轻相关。
- 8例(19%)报告短暂轻微急性不良反应,1例(2%)发生治疗相关严重不良事件(急性短暂焦虑)。
临床怎么用
- 对于伴或不伴致命疾病的焦虑患者,LSD辅助治疗可能作为改善焦虑及共病抑郁的候选干预,但需在严密监测下进行。
局限性
- 因存在遗留效应,结果主要展示第一周期(组间分析)的数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to investigate the efficacy and safety of lysergic acid diethylamide (LSD)-assisted therapy in patients who experienced anxiety with or without association with a life-threatening illness. METHODS: The study is an investigator-initiated 2-center trial that used a double-blind, placebo-controlled, 2-period, random-order, crossover design with 2 sessions with either oral LSD (200 μg) or placebo per period. The primary end point was anxiety symptoms 16 weeks after the last treatment session, assessed by the Spielberger State-Trait Anxiety Inventory-Global score in 42 patients. Further outcome measures included ratings for depression symptoms (Beck Depression Inventory and Hamilton Depression Rating Scale, 21-item version) and ratings for acute subjective drug effects. The outcomes for the first period (between-subjects analysis) are primarily shown due to carryover effects. RESULTS: LSD treatment resulted in significant reductions of State-Trait Anxiety Inventory-Global scores up to 16 weeks after treatment (least-square mean [standard error] change from baseline difference = -16.2 [5.8], 95% CI, -27.8 to -4.5, d = -1.18, p = .007). Similar effects were observed for ratings of comorbid depression on the Hamilton Depression Rating Scale, 21-item version (-7.0 [1.9], 95% CI, -10.8 to -3.2, d = -1.1, p = .0004) and the Beck Depression Inventory (-6.1 [2.6], 95% CI, -11.4 to -0.9, d = -0.72, p = .02). Positive acute subjective drug effects and mystical-type experiences correlated with the long-term reductions in anxiety symptoms. Transient, mild, acute untoward effects of LSD treatment were reported by 8 patients (19%). One treatment-related serious adverse event (acute transient anxiety) occurred (2%). CONCLUSIONS: LSD produced long-lasting and notable reductions in anxiety and comorbid depression symptoms up to 16 weeks.
引用
- Holze F, Gasser P, Müller F, et al. Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. Biol Psychiatry. 2022. PMID: 36266118. doi:10.1016/j.biopsych.2022.08.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。